The Phase 2 trial reported by Diamond et al
How do Melanotan-1 and Melanotan-2 differ in their mechanisms of action
Peptide Vials (10 mg research vial assumed) At 1.75 mg per dose and 8 doses per month maximum, one 10 mg vial covers approximately 5-6 label-allowed doses
approved 2019 for HSDD in premenopausal women PMC (2022) Bremelanotide for treatment of female hypoactive sexual desire: mechanism, trials, and safety review ResearchGate (2022) Effect of bremelanotide on body weight of obese women: data from two phase 1 randomized controlled trials Mayo Clinic Bremelanotide (subcutaneous route): side effects, dosage, and precautions MedlinePlus Patient instructions for subcutaneous injections: site rotation and technique CDC Vaccine administration: subcutaneous route (angle, site, and no-aspiration guidance) CDC Vaccine administration best practices: during the injection (technique diagram) CDC Storage and handling of immunobiologics: cold-chain and lyophilized product guidance PMC (2019) Bremelanotide: first approval (comprehensive drug profile including cardiovascular considerations) NCBI Bookshelf Best practices for injection (asepsis, preparation, and administration) Diamond LE et al., J Sex Med (2006) Double-blind, placebo-controlled evaluation of intranasal bremelanotide (PT-141) in men with erectile dysfunction Diamond LE et al., J Sex Med (2006) An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141) Molinoff PB et al., Ann N Y Acad Sci (2003) PT-141: a melanocortin agonist for the treatment of sexual dysfunction (pharmacology and early clinical data) Kingsberg SA et al., Obstet Gynecol (2019) Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials (RECONNECT
Dermatol Clin
